MS-275 and Azacitidine in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia

Study Overview
=================
Brief Summary
-----------------
MS-275 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving MS-275 together with azacitidine may kill more cancer cells. This phase I trial is studying the side effects and best dose of MS-275 when given together with azacitidine in treating patients with myelodysplastic syndromes, chronic myelomonocytic leukemia, or acute myeloid leukemia.

Detailed Description
-----------------
OBJECTIVES: I. Determine the safety and toxicity of MS-275 and azacitidine in patients with myelodysplastic syndromes, chronic myelomonocytic leukemia, or acute myeloid leukemia. II. Determine the maximum tolerated dose and optimal phase II dose of MS-275 when combined with azacitidine in these patients. III. Determine, preliminarily, the potential therapeutic activity of this regimen in these patients. IV. Correlate MS-275 pharmacokinetics with clinical response and laboratory correlative endpoints in patients treated with this regimen. OUTLINE: This is a multicenter, dose-escalation study of MS-275. Patients receive azacitidine subcutaneously on days 1-10 and oral MS-275 on days 3 and 10. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of MS-275 until the maximum tolerated dose (MTD) is determined. Patients receive adjusted doses of azacitidine based on clinical response. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Up to 9 additional patients are treated at the MTD. [Note: Patients who do not achieve hematologic improvement or partial or complete response but who have stable disease after 4 courses of therapy may receive an additional 4 courses of therapy at a higher dose than what was originally assigned]

Official Title
-----------------
A Dose-Finding Trial of the Histone Deacetylase Inhibitor MS-275 (NSC 706995) in Combination With 5-Azacitidine (5AC, NSC 102816) in Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMMoL) and Acute Myeloid Leukemia (AML)

Conditions
-----------------
Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndrome, Leukemia, Myelodysplastic Syndrome, Recurrent Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndrome

Intervention / Treatment
-----------------
* Drug: Azacitidine
* Drug: Entinostat


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of 1 of the following: Histologically confirmed myelodysplastic syndromes (MDS) by bone marrow aspiration and/or biopsy International Prognostic Scoring System (IPSS) score of intermediate-1, intermediate-2, or high International Prognostic Scoring System (IPSS) score of intermediate-1, intermediate-2, or high Low IPSS score allowed provided patient has a clinically significant cytopenia (i.e., absolute neutrophil count < 1,000/mm^3, untransfused hemoglobin < 8 g/dL, platelet count < 20,000/mm^3, or anemia requiring transfusion) Chronic myelomonocytic leukemia Acute myeloid leukemia (AML) Relapsed or refractory disease Untreated AML allowed provided patient meets >= 1 of the following criteria: Age 60 and over AML arising in the setting of an antecedent hematologic disorder High-risk cytogenetic abnormalities Medical conditions that may compromise the ability to give cytotoxic chemotherapy as the primary modality Refused cytotoxic chemotherapy WBC < 30,000/mm3 for >= 2 weeks before study entry Acute promyelocytic leukemia allowed provided patient is in at least second relapse and has already received treatment regimens containing arsenic trioxide and isotretinoin No clinical evidence of CNS or pulmonary leukostasis or CNS leukemia Peformance status: Zubrod 0-2 Life expectancy: At least 6 months Hematopoietic: See Disease Characteristics Hemoglobin ≥ 8 g/dL (transfusion allowed) No disseminated intravascular coagulation Renal: Creatinine normal OR Creatinine clearance >= 60 mL/min Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception during and for 3 months after study treatment No untreated, active infection No other serious or uncontrolled medical condition More than 3 weeks since prior hematopoietic growth factors for this malignancy At least 3 weeks since prior hydroxyurea (2 weeks for AML patients) No concurrent hydroxyurea Recovered from all prior therapy At least 2 weeks since prior cytotoxic therapy (AML patients) More than 3 weeks since other prior therapy for this malignancy No other concurrent investigational or commercial agents or therapies for this malignancy No concurrent valproic acid Hepatic: Bilirubin normal unless due to hemolysis or Gilbert's syndrome AST and ALT =< 2.5 times upper limit of normal

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Arm I<br>Patients receive azacitidine subcutaneously on days 1-10 and oral MS-275 on days 3 and 10. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses* of MS-275 until the maximum tolerated dose (MTD) is determined. Patients receive adjusted doses of azacitidine based on clinical response. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Up to 9 additional patients are treated at the MTD. | Drug: Azacitidine<br>* Given SC<br>* Other names: Vidaza;Drug: Entinostat<br>* Given orally<br>* Other names: SNDX-275;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Maximum tolerated dose of MS-275 in combination with 5-azacitidine, assessed using Common Toxicity Criteria version 3.0 |  | 4 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Response rate measured by IWG criteria |  | 16 weeks | 
| Optimal dose combination |  | At study completion | 
| Levels of histone acetylation and gene re-expression |  | 4 weeks |